Literature DB >> 11149596

Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.

J P Cogswell1, C E Brown, J E Bisi, S D Neill.   

Abstract

Polo-like kinase 1 (PLK1), which has been shown to have a critical role in mitosis, is one possible target for cancer therapeutic intervention. PLK1, at least in Xenopus, starts the mitotic cascade by phosphorylating and activating cdc25C phosphatase. Also, loss of PLK1 function has been shown to induce mitotic catastrophe in a HeLa cervical carcinoma cell line but not in normal Hs68 fibroblasts. We wanted to understand whether the selective mitotic catastrophe in HeLa cells could be extended to other tumor types, and, if so, whether it could be attributable to a tumor-specific loss of dependence on PLK1 for cdc25C activation. When PLK1 function was blocked through adenovirus delivery of a dominant-negative gene, we observed tumor-selective apoptosis in most tumor cell lines. In some lines, dominant-negative PLK1 induced a mitotic catastrophe similar to that published in HeLa cells (K. E. Mundt et al., Biochem. Biophys Res. Commun., 239: 377-385, 1997). Normal human mammary epithelial cells, although arrested in mitosis, appeared to escape the loss of centrosome maturation and mitotic catastrophe seen in tumor lines. Mitotic phosphorylation of cdc25C and activation of cdk1 was blocked by dominant-negative PLK1 in human mammary epithelial cells as well as in the tumor lines regardless of whether they underwent mitotic catastrophe. These data strongly argue that the mitotic catastrophe is not attributable to a lack of dependence for PLK1 in activating cdc25C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149596

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  28 in total

1.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

2.  The tumor suppressor CYLD regulates entry into mitosis.

Authors:  Frank Stegmeier; Mathew E Sowa; Grzegorz Nalepa; Steven P Gygi; J Wade Harper; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-10       Impact factor: 11.205

3.  The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.

Authors:  Chengfu Yuan; Lei Wang; Liang Zhou; Zheng Fu
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

Review 4.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

5.  Decoding ubiquitin for mitosis.

Authors:  Sadek Fournane; Ksenia Krupina; Charlotte Kleiss; Izabela Sumara
Journal:  Genes Cancer       Date:  2012-11

6.  Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

Authors:  Franz Rödel; Sarah Keppner; Gianni Capalbo; Robina Bashary; Manfred Kaufmann; Claus Rödel; Klaus Strebhardt; Birgit Spänkuch
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

Review 7.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

8.  Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation.

Authors:  Hyungshin Yim; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

9.  RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis.

Authors:  Victoria Sherwood; Ria Manbodh; Carol Sheppard; Andrew D Chalmers
Journal:  Mol Biol Cell       Date:  2008-02-13       Impact factor: 4.138

10.  Selection of hyperfunctional siRNAs with improved potency and specificity.

Authors:  Xiaowei Wang; Xiaohui Wang; Rajeev K Varma; Lesslie Beauchamp; Susan Magdaleno; Timothy J Sendera
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.